Piotrowska E, Piotrowski J, Grzeszczak W
Katedra i Klinika Chorób Wewnetrznych i Zawodowych, Zabrzu.
Pol Arch Med Wewn. 1993 Mar;89(3):207-11.
The liver microsomal enzymes activity was measured by aminopyrine breath test in 20 subjects with duodenal ulcer disease treated with famotidine for 8 weeks. Aminopyrine breath test was performed, before treatment (group I), after 4 weeks of therapy (group II) and after 8 weeks of treatment with famotidine (group III). The mean aminopyrine breath test value before treatment was 5.32% dose/h. After 4 weeks of treatment with famotidine statistically significant decrease of breath test values (x = 4.79% dose/h) was found. More strong microsomal enzymes inhibition was found after 8 weeks of famotidine therapy (x = 4.46% dose/h). These data indicate an inhibitory effect of famotidine on liver monooxygenases activity. In patients taking this drug, treatment with other drugs metabolised in liver and with drugs inhibiting the microsomal system must be very cautions.
采用氨基比林呼吸试验，对20例十二指肠溃疡疾病患者进行了为期8周的法莫替丁治疗，并测定了其肝微粒体酶活性。在治疗前（第一组）、治疗4周后（第二组）以及法莫替丁治疗8周后（第三组）进行了氨基比林呼吸试验。治疗前氨基比林呼吸试验的平均值为5.32%剂量/小时。法莫替丁治疗4周后，呼吸试验值出现了统计学上的显著下降（x = 4.79%剂量/小时）。法莫替丁治疗8周后，发现微粒体酶抑制作用更强（x = 4.46%剂量/小时）。这些数据表明法莫替丁对肝脏单加氧酶活性具有抑制作用。在服用该药物的患者中，使用其他在肝脏代谢的药物以及抑制微粒体系统的药物时必须非常谨慎。
